Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
Target therapy with sorafenib is the standard of treatment for advanced Hepatocellular carcinoma (HCC), but the patient survival time is still unsatisfactory. The aims of this study are to prove statins improve the tumor responses and overall survival for patients who receive sorafenib therapy for advanced HCC by a prospective randomized controlled study.
Epistemonikos ID: ef18dffc4334356aec8b92e45395c3c0c968c4ea
First added on: May 21, 2024